ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: Pain Therapeutics Inc. (PTIE) Report Updated: May 13, 2013 | Print This Page

Get more stock ratings by Louis Navellier

Pain Therapeutics Inc. (PTIE)

Rating: Sell Volatility: Aggressive
Total Grade: D Industry: Pharmaceuticals
Competitors: JNJ, SNTS, TARO, PFE
hide

Stock Analysis

Rating: Monthly View

A
B
C
D
F
May June July August September October November December January February March April

Rating: Weekly View

This Week: D down downgrade
Last Week: C same no change
Two Weeks Ago: C up no change
service keys
hide

Pain Therapeutics Inc.© quotemedia

hide

Company Profile

Pain Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel drugs. Its lead drug candidate is REMOXY painkiller, a novel controlled-release oral capsule form of oxycodone in a viscous liquid formulation matrix that includes novel excipients. REMOXY is formulated to help address issues of abuse and misuse of time-release oxycodone tablets. The company’s other product candidates comprise hydromorphone, hydrocodone, and oxymorphone, which are abuse-resistant opioid product candidates. Pain Therapeutics, Inc. has strategic alliance with Pfizer, Inc. under the King Pharmaceutical, Inc. agreements for the development of REMOXY, as well as hydromorphone, hydrocodone, and oxymorphone. The company was founded in 1998 and is based in Austin, Texas.